Variability in immunophenotype in diffuse large B‐cell lymphoma and its clinical relevance

Publisher Website
Google Scholar
Abstract
Diffuse large B‐cell lymphoma (DLBCL), the single largest category of lymphoma, is a clinically and biologically heterogeneous disease entity. Clinically, patients differ in their mode of presentation and respond variably to therapy. A combination of clinical parameters can be used to predict the patient's response to therapy and survival. The pathological variability of DLBCL is expressed in morphology, immunophenotype, cytogenetic and molecular genetic features. Numerous markers detectable by immunohistochemistry and linked to different aspects of tumour biology have been studied in DLBCL, including lineage‐associated and immune markers, proliferation and apoptosis markers, cell adhesion molecules, and more recently stage‐specific markers of B‐cell differentiation. This review summarizes these studies in regard to their clinical significance and in the light of recent advances in our understanding of the molecular pathology and histogenesis of DLBCL.